|
PDUFA V Could Jeopardize U.S. Lead Over EU in Cancer Drug Approvals, Expert Says
A new study shows the U.S. outpaces Europe in approving new cancer drugs, but that lead could be in jeopardy under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), an expert tells IPRM.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives